Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Public ClinicalTrials.gov record NCT05798663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Study identification
- NCT ID
- NCT05798663
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 178 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2023
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2026
- Last update posted
- Jun 8, 2026
2023 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego Moores Cancer Center | La Jolla | California | 92037 | — |
| Kaiser Permanente Oakland Medical Center | Oakland | California | 94611 | — |
| Kaiser Permanente Roseville Medical Center | Roseville | California | 95661 | — |
| Kaiser Permanente San Francisco Medical Center | San Francisco | California | 94115 | — |
| Kaiser Permanente Santa Clara Medical Center | Santa Clara | California | 95051 | — |
| Kaiser Permanente Vallejo Medical Center | Vallejo | California | 94589 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Washington University Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Missouri Baptist Medical Center | St Louis | Missouri | 63131 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| New Hampshire Oncology - Hematology, PA | Manchester | New Hampshire | 03103 | — |
| Hematology Oncology Associates of Central New York, P.C. | East Syracuse | New York | 13057 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05798663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05798663 live on ClinicalTrials.gov.